A retrospective and prospective overview of prostate-specific antigen

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 11-12, 1997, Pages 583-594

  Ablin, Richard J ^a  

^a Tetragenex Pharmaceuticals Inc   (United States)

Author keywords

Benign prostatic hyperplasia; Prostate cancer; Prostate specific antigen (PSA); PSA functions; PSA related concepts (indices) Ultrasensitive PSA assays

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031440038     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050110     Document Type: Review

References (119)

1. Ablin RJ (1972) Immunologic studies of normal, benign and malignant human prostatic tissue. Cancer 29:1570-1574
2. Ablin RJ (1977) Immunobiology of the prostate. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 33-98
3. Ablin RJ (1979) Localization of prostatic tissue-specific acid phosphatase as a possible biological marker of malignancy. In: Peeters H (ed) Protides of biological fluids. Pergamon, Oxford, pp 225-228
4. Ablin RJ (1983) Immunological aspects of benign prostatic hypertrophy. In: Hinman F Jr (ed) Benign prostatic hypertrophy. Springer, New York, pp 73-98
5. Ablin RJ (1989) Prostate-specific antigen in the female prostate (letter). Clin Chem 35:507-508
6. Ablin RJ (1993) Circulating prostate specific antigen-positive cells correlate with metastatic cancer (letter). Br J Urol 71:761-762
7. Ablin RJ, Whyard TC (1990) Immunobiological implications of select molecules in the prostate with a known and unknown target. In: Farnsworth WE, Ablin RJ (eds) The prostate as an endocrine gland. CRC, Boca Raton, Fla, pp 149-172
8. Ablin RJ, Bronson P, Soanes WA, Witebsky E (1970a) Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 104:1329-1339
9. Ablin RJ, Soanes WA, Bronson P, Witebsky E (1970b) Precipitating antigens of the normal human prostate. J Reprod Fertil 22:573-574
10. 2-globulin and the clinical response in patients with prostatic cancer following cryotherapy. Oncology 32:127-144
11. Ablin RJ, Bartkus JM, Gonder MJ, Polgar J (1987) Factors contributing to suppression of tumour-host responsiveness. In: Cimino F, Birkmayer CD, Pimentel E, Klavins JV, Salvatore F (eds) Human tumour markers - biology and clinical applications. Walter de Gruyter, Berlin, pp 279-299
12. Armbruster DA (1993) Prostatic-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39:181-195
13. Ban Y, Wang MC, Watt KWK, Loor R, Chu TM (1984) The proteolytic activity of human prostate-specific antigen. Biochem Biophy Res Commun 123:482-488
14. Baserga R (1995) Insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249-252
15. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147:817-821
16. Bilgrami S, Singh NT, Shafi N, Ciesielski T (1994) Raised prostate-specific antigen in adenocarcinoma of lung. Lancet 344:1371-1372
17. 1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 42:502-510
18. 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43:427-434
19. Bostwick DG, Qian J (1994) Current and proposed biologic markers in prostate cancer: 1994. J Cell Biochem 19 [Suppl]:197-201
20. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, Assmann G, Zänker KS (1996) Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Res 56:4556-4561
21. Brawer MK, Lange PH (1989) Prostate-specific antigen: Its role in early detection, staging, and monitoring patients with prostatic carcinoma. J Endourol 3:227-236
22. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH (1993) Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 150:106-109
23. Bunting PS (1995) A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 28:221-241
24. Bush IM, Berman E, Nourkayhan S, Bush RB, Sadoughi N, Guinan P, Zamm A, Ablin RJ (1974) Zinc and the prostate (abstract). In: American Urological Association, 69th Annual Meeting, St. Louis, Mo. Williams, Williams, Baltimore p 110
25. Carter HB, Pearson JD, Metter J, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh P (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J Am Med Assoc 267:2215-2220
26. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan J, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 324:1156-1161
27. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL et al. (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290
28. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL (1995) Increased specificity of PSA screening through measurement of percent free PSA in serum (abstract). J Urol 153 [Suppl 4]:312A
29. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC (1987) Prostate-specific antigen as a marker for prostate cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 33:1916-1920
30. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105
31. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG (1994) Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142:407-415
32. Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG (1997) Early detection of prostate cancer. II. Estimating the risks, benefits, and costs. Ann Intern Med 126:468-479
33. Cooner WH, Mosley BR, Rutherford CL, Jr., Beard JH, Pond HS, Terry WJ, Kidd DD (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1154
34. Dalkin BL, Ahmann F, Southwick P, Bottaccini MR (1993) Derivation of normal prostate-specific antigen (PSA) level by age (abstract). J Urol 149 [Suppl]:413A
35. Deguchi T, Doi T, Ehara H, Ho S-I, Takahashi Y, Nishino Y, Fujihiro S, Kawamura T, Komeda H, Horie M, Kaji H, Shimokawa K, Tanaka T, Kawada Y (1993) Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 53:5350-5354
36. Diamandis EP, Yu H, Sutherland JA (1994) Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32:301-310
37. Diamandis EP, Yu H, Melegos DN (1996) Ultrasensitive prostate-specific antigen assays and their clinical application. Clin Chem 42:853-857
38. 2 adenocarcinoma of the prostate. Prognostic implications. Hum Pathol 15:853-859
39. Flocks RH, Urich VC, Patel CA, Opitz JM (1960) Studies on the antigenic properties of prostatic tissue I. J Urol 84:134-143
40. Glenski WJ, Malek RS, Myrtle JF, Oesterling JE (1992) Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clin Proc 67:249-252
41. Goldfarb DA, Stein BS, Shamszadeh M, Petersen RO (1986) Age-related changes in tissue levels of prostatic acid phophatase and prostate specific antigen. J Urol 136:1266-1269
42. Goldrath DE, Messing EM (1989) Prostate-specific antigen: not detectable despite tumor progression after radical prostatectomy. J Urol 142:1082-1084
43. Hamdy FC, Lawry J, Anderson JB, Parsons MA, Rees RC, Williams JL (1992) Circulating prostate specific antigen-positive cells correlate with metastatic cancer. Br J Urol 69:392-396
44. Hara M, Koyanagi Y, Inoue T, Fukuyara T (1971) Some physicochemical characteristics of gamma-seminoprotein: an antigenic component specific for human seminal plasma (in Japanese). Jpn J Legal Med 25:322-324
45. 2-macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 37:917-923
46. Hortin GL, Bahnson RR, Draft M, Chan K-M, Catalona WJ, Ladenson JH (1988) Differences in values obtained with 2 assays of prostate specific antigen. J Urol 139:762-765
47. Hudson MA, Bahnson RR, Catalona WJ (1989) Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol 142:1011-1017
48. Hunt P, Eardley DD (1986) Suppressive effects of insulin and insulin-like growth factor-1 (IGF-1) on immune responses. J Immunol 136:3994-3999
49. Irani J, Millet C, Levillian P, Doré B, Begon F, Aubert J (1996) Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer. Eur Urol 29:407-417
50. Irani J, Millet C, Levillian P, Doré B, Begon F, Aubert J (1997) Serum-to-urinary prostate specific antigen ratio: Its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng/ml. J Urol 157:185-188
51. Iwamura M, Hellman J, Cockett ATK, Lija H, Gershagen S (1996) Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48:317-325
52. Junker R, Brandt B, Semjonow A, Assmann G (1996) Measurement of prostate-specific antigen: No advantage to ultrasensitive assays? (correspondence). J Natl Cancer Inst 88:1594-1595
53. Kane RA, Littrup PJ, Babaian R, Drago JR, Lee F, Chesley A, Murphy GP, Mettlin C, Investigators of the American Cancer Society National Prostate Cancer Detection Project (1992) Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 69:1201-1207
54. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R (1994) Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43:765-775
55. Keillor JS, Aterman K (1993) The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study. J Urol 137:894-896
56. Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, Slack NH, Papsidero LD, Murphy GP, Chu TM, Investigators of the National Prostatic Cancer Project (1985) Prognostic importance of prostatic specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 45:886-891
57. Killian CS, Emrich LJ, Yang N, Wang MC, Priore RL, Murphy GP, Chu TM (1986) Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 76:179-185
58. Killian CS, Corral DA, Kawinski E, Constantine RI (1993) Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192:940-947
59. Kreisle W, Ahmann R, Feinberg W, Corrigan J (1990) Prostate-specific antigen (PSA) levels and coagulation abnormalities in prostate cancer (abstract). Proc Am Assoc Cancer Res 31:168
60. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, Nishiura T, Murphy GP, Chu TM (1980) Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40:4658-4662
61. Kuriyama M, Wang MC, Lee C-L, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM (1981) Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874-3876
62. Labrie F, Dupont A, Suburu R, Cusan L, Temblay J-L, Gomez JL, Emond J (1992) Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 147:846-852
63. Lee F, Littrup PJ, Loft-Christensen L, Kelly BS, Jr., McHugh TA, Siders DB, Mitchell AE, Newby JE (1992) "Predicted" prostate specific antigen results using transrectal ultrasound gland volume: differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 70 [Suppl]:211-220
64. 1-antichymotrypsin. Clin Chem 39:2098-2103
65. Li TS, Beling CG (1973) Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 24:134-143
66. Lilja HJ (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. Clin Invest 76:1899-1903
67. Lilja H, Oldbring J, Rannevik G, Laurell C-B (1987) Seminal vesicle secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80:281-285
68. 1antichymotrypsin. Clin Chem 37:1618-1625
69. Littrup PJ, Kane RA, Williams CR, Egglin TK, Lee F, Torp-Pedersen S, Church PA (1991a) Determination of prostate volume with transrectal US and cancer screening. I. Comparison with prostate-specific antigen assays. Radiology 178:537-542
70. Littrup, PJ, Williams CR, Egglin TK, Kane RA (1991b) Determination of prostate volume with transrectal US for cancer screening. II. Accuracy of in vitro and in vivo techniques. Radiology 179:49-53
71. Littrup PJ, Lee F, Mettlin C (1992) Prostate cancer screening: current trends and future implications. CA 42:198-211
72. Mettlin CJ, Lee F, Drago J, Murphy GP (1991) The American Cancer Society National Prostatic Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 67:2949-2958
73. Miyashita H, Watanabe H, Ohe H, Saithoh M, Oogama Y, Iijima S (1984) Transrectal ultrasonotomography of the canine prostate. Prostate 5:453-457
74. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Gant Mulholland S, Comelia LG (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110-6112
75. Morton RA, Madewell LM, Ewing CM, Gingrich J, Greenberg NM, Isaacs WB (1996) Molecular mechanisms of prostate cancer progression. Proc Am Assoc Cancer Res 37:627-628
76. Muir SC, Nectoux J, Staszewski J (1991) The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 30:133-140
77. Müntzing J, Nilsson T, Polacek J (1974) Zinc and β-glucuronidase in the human prostate. Scand J Urol Nephrol 8:87-90
78. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR (1981) Prostatic-specific antigen: an immunohistologic marker for prostate neoplasms. Cancer 48:1229-1232
79. Nairn RC, Richmond HG, McEntegart MG, Fothergill JE (1960) Immunological differences between normal and malignant cells. Br Med J 2:1335-1340
80. Newling DWW (1995) Update on urology - prostate cancer. I. The molecular basis for prostatic cancer: how it may influence treatment choice. Eur J Surg Oncol 21:310-315
81. Nixon RG, Wener MH, Smith KM, Parson RE, Strobel SA, Brawer MK (1997) Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol 157:2183-2190
82. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Jr. Bruzek DJ, Rock RC, Brendler CB, Walsh PC (1988) Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139:766-772
83. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993a) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J Am Med Assoc 270:860-864
84. Oesterling JE, Cooner WH, Jacobsen SJ, Guess HA, Lieber MM (1993b) Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 20:671-680
85. Oesterling JE, Martin SK, Bergstralh EJ, Yemoto EM, Stamey TA (1995) The periurethral glands do not have a clinically significant effect on the serum PSA concentration (abstract). J Urol 153 [Suppl 4]:518A
86. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM (1980) A prostate antigen in sera of prostatic cancer patients. Cancer Res 40:2428-2432
87. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics, 1997, CA 47:5-27
88. Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen: update 1994. J Urol 152:1358-1368
89. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC (1990) Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143:747-752
90. Pearson JD, Carter HB, Metter EJ, Chan DW, Landis P, Andres R, Walsh PC (1995) Sensitivity and specificity of age-specific reference ranges for PSA velocity (abstract). J Urol 153 [Suppl 4]:465A
91. Pienta KJ, Esper PS (1993) Risk factors for prostate cancer. Ann Int Med 118:793-808
92. Prestigiacomo AF, Stamey TA (1994) A comparison of 4 ultra-sensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol 152:1515-1519
93. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL Jr (1991) Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49:645-649
94. Proceedings of the American Urological Association (1995) 90th Annual Meeting, Las Vegas, Nevada, 23-28 April. J Urol 153 [Suppl 4]:1A-583A
95. Purnell DM, Heatfield BM, Trump BF (1984) Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, non-specific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res 44:285-292
96. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC (1993) Analysis of variations in prostate-specific antigen values. Urology 42:390-397
97. Robles JM, Morell AR, Redorta JP, Mateos JAD, Rosello AS (1988) Clinical behavior of prostatic specific antigen and prostatic acid phosphatase: a comparative study. Eur Urol 14:360-366
98. Scardino PT (1989) Early detection of prostate cancer. Urol Clin North Am 16:635-655
99. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L (1996) Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 7:3-16
100. Sensabaugh GF, Crim D (1978) Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 23:106-115
101. Sinha M, Wilson MJ, Gleason DF (1987) Immunoelectron microscopic localization of prostatic-specific antigen in human prostate by the protein A-gold complex. Cancer 60:1288-1293
102. Smith MR, Biggar S, Hussain M (1995) Prostate-specific antigen messenger RNA is expressed in non-prostatic cells: implications for detection of micrometastases. Cancer Res 55:2640-2644
103. Stamey TA (1996) Lower limits of detection, biological detection limits, functional sensitivity or residual cancer detection limit? Sensitivity reports on prostate specific antigen assays mislead clinicians. Clin Chem 42:849-852
104. Stamey TA, Kabalin JN (1989) Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. 1. Untreated patients. J Urol 141:1070-1075
105. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adeno-carcinoma of the prostate. N Engl J Med 317:909-916
106. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N (1989) Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy-treated patients. J Urol 141:1076-1083
107. Stege R, Lundh B, Tribukait B, Pousette A, Carlstrom K, Hasenson M (1990) Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 144:299-302
108. Stein BS, Vangore S, Peterson RO (1984) Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology 24:146-152
109. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226
110. 1antichymotrypsin before diagnosis of prostate cancer. Lancet 344:1594-1598
111. Takayama TK, Vessella RL, Brawer MK, Noteboom J, Lange PH (1993) The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J Urol 150:374-378
112. Tulinius H (1982) Latent malignancies. In: Grundmann E (ed) Cancer epidemiology, cancer campaign, vol 6. Fischer, Stuttgart New York, pp 129-137
113. Wang MC, Valenzuela LA, Murphy GP Chu TM (1979) Purification of a human prostate specific antigen. Invest Urol 17:159-163
114. Watt KWK, Lee PL, M'Timkulu T, Chan W-P, Loor R (1986) Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci (USA) 83:3166-3170
115. Whitmore WF Jr (1994) Localised prostatic cancer: management and detection issues. Lancet 343:1263-1267
116. Yu H, Diamandis EP (1995) Prostate-specific antigen in milk of lactating women. Clin Chem 41:54-58
117. Yu H, Diamandis P, Levesque M, Asa SL, Monne M, Croce CM (1995) Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55:1603-1606
118. Zagars GK, Pollack A (1993) The fall and rise of prostate-specific antigen. Cancer 72:832-842
119. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL (1993) Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39:2483-2491